Nathalie Lokker

Title: Nathalie Lokker: Innovator in Pharmaceutical Compositions

Introduction

Nathalie Lokker is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions and methods for inhibiting specific proteins. With a total of five patents to her name, Lokker's work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

One of Lokker's latest patents involves pharmaceutical pyrazole compositions that serve as inhibitors of protein kinases. This invention outlines a method for selectively inhibiting a kinase by contacting a composition containing the kinase with a specific compound formula. The patent details various substituents that can be used in the compound, showcasing the complexity and specificity of her work. Another notable patent focuses on inhibitory immunoglobulin polypeptides that bind to the human PDGF beta receptor. This invention aims to inhibit PDGF-induced receptor activation, which has implications for treating conditions related to cell migration and proliferation.

Career Highlights

Nathalie Lokker has established herself as a key figure in her field through her innovative research and patent contributions. Her work at Cor Therapeutics, Inc. has allowed her to collaborate with other experts and push the boundaries of pharmaceutical science. Her patents reflect a deep understanding of molecular interactions and therapeutic applications.

Collaborations

Throughout her career, Lokker has worked alongside notable colleagues such as Neill A Giese and Alan M Laibelman. These collaborations have enriched her research and contributed to the successful development of her patented inventions.

Conclusion

Nathalie Lokker's contributions to pharmaceutical innovations highlight her role as a leading inventor in the field. Her patents not only demonstrate her expertise but also pave the way for future advancements in medical therapies.